Technology Innovation Institute Announces Launch of NOOR, the World’s Largest Arabic NLP Model
11.4.2022 14:16:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), a global research center and applied research pillar of Abu Dhabi’s Advanced Technology Research Council, today announced the launch of NOOR, the world’s largest Arabic natural language processing (NLP) model to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005085/en/
Noor, the world's largest Arabic NLP Model - AI Cross-Center Unit, Technology Innovation Institute (Photo: AETOSWire)
TII’s team of advanced researchers and Artificial Intelligence (AI) specialists, has joined forces with LightOn, a technology company that unlocks extreme-scale machine intelligence for businesses, to transform the Arabic NLP model. The NOOR model has the capability to carry out tasks beyond the domain of language - offering end-to-end pipeline high quality data, including crawling, filtering, and curation at scale. The model facilitates extreme-scale distributed training and serving – to deliver applications with efficient inference and model specialization.
Dr. Ray O. Johnson, CEO, TII and ASPIRE, said: “With this development, we are well on track to enhance our research capabilities and credentials as well as elevate the status of Abu Dhabi and the UAE as a serious research ecosystem. Our expert teams have demonstrated yet again that this region can achieve breakthrough R&D outcomes to impact the world.”
Dr. Ebtesam Almazrouei, Director, AI Cross-Center Unit, TII, said: “Large language models have taken the world of natural language processing by storm, and we are proud to introduce this cutting-edge model with 10 billion parameters - the world’s largest Arabic NLP model. The uniquely large Arabic dataset collected to train the model is the result of months of work that included curating, scrapping, and filtering of varied sources. A special thank you to the entire team that worked on this project to make NOOR the go-to exploration model in Arabic for academicians and businesses everywhere.”
Speaking on the launch, Prof. Mérouane Debbah, Chief Researcher, Digital Science Research Center and AI Cross-Center Unit, TII, said: “With NOOR, TII has expanded the scope of the modern standard Arabic model by leveraging know-how in large language models to build cross-disciplinary, cutting-edge expertise in this new generation of AI research.”
To curate the world’s largest high-quality cross-domain Arabic datasets, NOOR’s unique dataset of more than 30 billion words combines web data with books, poetry, news articles, and technical information to significantly widen the applicability of the model.
Dr. Ebtesam Almazrouei said the NOOR model is based on the popular Transformer architecture. As a decoder-only model, similar in structure to GPT-3, it is programmed to tackle generative tasks with architecture upgraded to reflect the latest developments in the world of machine learning, including improvements such as better positional embeddings. To help ensure quality at scale in the NOOR dataset, the TII team designed an automated filtering pipeline based on machine learning techniques. These tools identify text like quality references and safeguard the model from exposure to spam content.
Leveraging state-of-the-art 3D parallelism, NOOR was trained on a High-Performance Computing resource with 128 A100 GPUs, allowing for the distribution of computations and ensuring efficient use of the available hardware resources.
The Director of the AI Cross-Center Unit noted that this was only the first step in the Unit’s efforts to contribute to the wider UAE Strategy for Artificial Intelligence.
Named for the Arabic word "light", the model has been so called to establish the correlation of the Arabic language model to enlightening the mind.
About Technology Innovation Institute (TII)
For more information, visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005085/en/
Contact information
Technology Innovation Institute
Sneha Sivanand, sneha.sivanand@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
